Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Table 4 Percentage of patients with adverse effects in real-world studies

Adverse effect	Matrana [28]*	US cohort [33]*	SPAZO [25]**
Fatigue	44%	56%	7.7%
AST^a/ALT^b	35%		3.9%/7.8%
Diarrhea	30%	52%	3.6%
Hypothyroidism	18%
Nausea/vomiting	17%	40%/44%	−/1.1%
Arterial hypertension	–	27%	4%
Anemia			2.6%
Dropout rate	12%		11.9%

^aAST aspartate aminotransferase; ^bALT alanine aminotransferase
*All grades adverse events according to CTCAE; **Only grade 3–4 adverse effects were reported

ISSN: 2050-6511